CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Bevacizumab (TBD) mCRC NSCLC Biosimilar – Details

Project Number pCODR 10178
Brand Name TBD
Generic Name Bevacizumab
Tumour Type Gastrointestinal / Lung
Indication Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer Biosimilar
Funding Request Metastatic Colorectal Cancer (mCRC); Non-Small Cell Lung Cancer (NSCLC)
Review Status File Closed
Pre Noc Submission Yes
NOC Date
Manufacturer Pfizer Canada Inc.
Sponsor Pfizer Canada Inc.
Submission Date March 14, 2019
Submission Deemed Complete March 28, 2019
Submission Type Biosimilar – New Drug
Prioritization Requested
Stakeholder Input Deadline ‡ March 28, 2019
Check-point meeting (target date)
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.